Overview

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patients.
Phase:
Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Cellular Biomedicine Group Ltd.